FRANKFURT (Reuters) -Swiss drugmaker Roche on Thursday lifted its full-year guidance after reporting nine-month sales that were better than expected. In a statement, the group said it expects a currency-adjusted increase in 2025 sales in the "mid single digit" percentage range. It also projected a gain in adjusted earnings per share in the "high single to low double digit" percentage range. (Reporting by Ludwig Burger, Editing by Miranda Murray) (The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
